Amarantus Bioscience Holdings Stock Performance
The firm shows a Beta (market volatility) of -1.56, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Amarantus Bioscience are expected to decrease by larger amounts. On the other hand, during market turmoil, Amarantus Bioscience is expected to outperform it. At this point, Amarantus Bioscience has a negative expected return of -2.69%. Please make sure to confirm Amarantus Bioscience's risk adjusted performance, variance, as well as the relationship between the Variance and kurtosis , to decide if Amarantus Bioscience performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Amarantus Bioscience Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Amarantus |
Amarantus Bioscience Relative Risk vs. Return Landscape
If you would invest 0.03 in Amarantus Bioscience Holdings on November 10, 2025 and sell it today you would lose (0.03) from holding Amarantus Bioscience Holdings or give up 100.0% of portfolio value over 90 days. Amarantus Bioscience Holdings is currently does not generate positive expected returns and assumes 15.1476% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Amarantus, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Amarantus Bioscience Target Price Odds to finish over Current Price
The tendency of Amarantus Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.00 | 90 days | 0.00 | about 77.21 |
Based on a normal probability distribution, the odds of Amarantus Bioscience to move above the current price in 90 days from now is about 77.21 (This Amarantus Bioscience Holdings probability density function shows the probability of Amarantus Pink Sheet to fall within a particular range of prices over 90 days) .
Amarantus Bioscience Price Density |
| Price |
Predictive Modules for Amarantus Bioscience
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Amarantus Bioscience. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Amarantus Bioscience Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Amarantus Bioscience is not an exception. The market had few large corrections towards the Amarantus Bioscience's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Amarantus Bioscience Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Amarantus Bioscience within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.9 | |
β | Beta against Dow Jones | -1.56 | |
σ | Overall volatility | 0.0001 | |
Ir | Information ratio | -0.13 |
Amarantus Bioscience Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Amarantus Bioscience for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Amarantus Bioscience can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Amarantus Bioscience generated a negative expected return over the last 90 days | |
| Amarantus Bioscience has high historical volatility and very poor performance | |
| Amarantus Bioscience has some characteristics of a very speculative penny stock | |
| Amarantus Bioscience has a very high chance of going through financial distress in the upcoming years | |
| Amarantus Bioscience Holdings currently holds 20.72 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Amarantus Bioscience has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Amarantus Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Amarantus Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amarantus Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amarantus to invest in growth at high rates of return. When we think about Amarantus Bioscience's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (10.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Amarantus Bioscience Holdings currently holds about 178 in cash with (1.8 M) of positive cash flow from operations. |
Amarantus Bioscience Fundamentals Growth
Amarantus Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Amarantus Bioscience, and Amarantus Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amarantus Pink Sheet performance.
| Current Valuation | 6.59 M | |||
| Shares Outstanding | 68.27 M | |||
| Price To Earning | (0.01) X | |||
| Price To Book | 53.19 X | |||
| EBITDA | (20.79 M) | |||
| Cash And Equivalents | 178 | |||
| Total Debt | 20.72 M | |||
| Debt To Equity | 0.84 % | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (1.8 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 3.48 M | |||
| Retained Earnings | (104.87 M) | |||
| Current Asset | 942 K | |||
| Current Liabilities | 15.83 M | |||
About Amarantus Bioscience Performance
Assessing Amarantus Bioscience's fundamental ratios provides investors with valuable insights into Amarantus Bioscience's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Amarantus Bioscience is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York. Amarantus Bioscience operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Amarantus Bioscience performance evaluation
Checking the ongoing alerts about Amarantus Bioscience for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Amarantus Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Amarantus Bioscience generated a negative expected return over the last 90 days | |
| Amarantus Bioscience has high historical volatility and very poor performance | |
| Amarantus Bioscience has some characteristics of a very speculative penny stock | |
| Amarantus Bioscience has a very high chance of going through financial distress in the upcoming years | |
| Amarantus Bioscience Holdings currently holds 20.72 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Amarantus Bioscience has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Amarantus Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Amarantus Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amarantus Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amarantus to invest in growth at high rates of return. When we think about Amarantus Bioscience's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (10.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Amarantus Bioscience Holdings currently holds about 178 in cash with (1.8 M) of positive cash flow from operations. |
- Analyzing Amarantus Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Amarantus Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Amarantus Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Amarantus Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Amarantus Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Amarantus Bioscience's pink sheet. These opinions can provide insight into Amarantus Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Amarantus Pink Sheet Analysis
When running Amarantus Bioscience's price analysis, check to measure Amarantus Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amarantus Bioscience is operating at the current time. Most of Amarantus Bioscience's value examination focuses on studying past and present price action to predict the probability of Amarantus Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amarantus Bioscience's price. Additionally, you may evaluate how the addition of Amarantus Bioscience to your portfolios can decrease your overall portfolio volatility.